AllianceBernstein
RLMD icon

AllianceBernstein’s Relmada Therapeutics RLMD Stock Holding History

AllianceBernstein’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$276K Buy
+39,600
New +$277K ﹤0.01% 3023
2023
Q2 		– Sell
-30,400
Closed -$68.7K – 3233
2023
Q1 		$68.7K Hold
30,400
– – ﹤0.01% 3061
2022
Q4 		$106K Buy
30,400
+12,500
+70% +$110K ﹤0.01% 3110
2022
Q3 		$663K Sell
17,900
-59,132
-77% -$1.64M ﹤0.01% 2508
2022
Q2 		$1.46M Buy
77,032
+59,132
+330% +$1.29M ﹤0.01% 2145
2022
Q1 		$483K Hold
17,900
– – ﹤0.01% 2699
2021
Q4 		$403K Hold
17,900
– – ﹤0.01% 2825
2021
Q3 		$469K Hold
17,900
– – ﹤0.01% 2777
2021
Q2 		$573K Buy
17,900
+2,200
+14% +$76.4K ﹤0.01% 2758
2021
Q1 		$553K Hold
15,700
– – ﹤0.01% 2626
2020
Q4 		$503K Sell
15,700
-1,700
-10% -$58.4K ﹤0.01% 2590
2020
Q3 		$655K Sell
17,400
-600
-3% -$23.2K ﹤0.01% 2394
2020
Q2 		$806K Buy
+18,000
New +$761K ﹤0.01% 2309

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AllianceBernstein's RLMD Position: Q2 2026 in Review

AllianceBernstein opened a new position in Relmada Therapeutics (RLMD) in Q2 2026: 39,600 shares worth $276K. The stake represents ﹤0.01% of the portfolio and ranks #3023 among its holdings. This is a return to the name: AllianceBernstein previously reported a position in RLMD as recently as Q1 2023.

AllianceBernstein first reported a position in RLMD in Q2 2020 and has held it in 13 quarters since. The position peaked at $1.46M in Q2 2022. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • AllianceBernstein held 39,600 shares of Relmada Therapeutics worth $276K as of Q2 2026.
  • Relmada Therapeutics was a new AllianceBernstein position in Q2 2026.
  • Relmada Therapeutics made up ﹤0.01% of AllianceBernstein's portfolio in Q2 2026, its #3023 holding.
  • AllianceBernstein first reported a position in Relmada Therapeutics in Q2 2020 and has held it in 13 quarters since.
  • AllianceBernstein's Relmada Therapeutics position peaked at $1.46M in Q2 2022.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.